Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 1, 2012, Pages 91-98

  Fregonese, Federica ^a,b,c,d   Collins, Intira J ^a,b,c,e   Jourdain, Gonzague ^a,b,c   LeCoeur, Sophie ^a,b,c,f   Cressey, Tim R ^a,b,c   Ngo Giang Houng, Nicole ^a,b,c   Banchongkit, Sukit ^g   Chutanunta, Apichat ^h   Techapornroong, Malee ⁱ   Lallemant, Marc ^a,b,c  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PADOVA   (Italy)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f Université Paris Descartes   (France)

^g Rayong Hospital   (Thailand)

^h Samutsakhon General Hospital   (Thailand)

ⁱ PRAPOKKLAO HOSPITAL   (Thailand)

Author keywords

Antiretroviral therapy; HAART; HIV; Survival; Thailand

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG RESPONSE; EARLY MORTALITY; FEMALE; FOLLOW UP; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM MORTALITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; THAILAND; TREATMENT DURATION; VIRUS LOAD;

ADULT; ANEMIA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; THAILAND; VIRAL LOAD;

EID: 84862126574     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824bd33f     Document Type: Article

References (46)

1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report, 2010. Available at: http://www.who.int/hiv/pub/2010progressreport/en/index.html. Accessed December 21, 2011.
2. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-299.
3. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1- infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50: 1387-1396.
4. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.
5. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362:679-686.
6. Grabar S, Le Moing V, Goujard C, et al. Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J Acquir Immune Defic Syndr. 2005;39:284-292. (Pubitemid 40923207)
7. Harris RJ, Sterne JA, Abgrall S, et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther. 2008;13:959-967.
8. Mocroft A, Ledergerber B, Zilmer K, et al. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS. 2007;21:1867-1875. (Pubitemid 47329763)
9. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
10. Chasombat S, McConnell MS, Siangphoe U, et al. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr. 2009;50:506-512.
11. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129. (Pubitemid 34786200)
12. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181-1189. (Pubitemid 43786107)
13. Ferradini L, Laureillard D, Prak N, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS. 2007;21: 2293-2301. (Pubitemid 350287455)
14. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897-1908.
15. Tuboi SH, Schechter M, McGowan CC, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr. 2009;51:615-623.
16. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS. 2010;5:18-26.
17. Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS. 2008;22:2303-2311.
18. De Beaudrap P, Etard JF, Ecochard R, et al. Change over time of mortality predictors after HAART initiation in a Senegalese cohort. Eur J Epidemiol. 2008;23:227-234.
19. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS. 2009;23:335-342.
20. National AIDS Prevention and Alleviation Committee. UNGASS Country Progress Report-Thailand. Reporting Period January 2008-December 2009. Available at: http://www.unaids.org/en/dataanalysis/monitoringcountryprogress/ 2010progressreportssubmittedbycountries/thailand-2010-country-progress-report- en.pdf. Accessed December 21, 2011.
21. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med. 2000;343:982-991.
22. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217-228.
23. World Health Organization. Scaling up antiretroviral therapy in resourcelimited settings: guidelines for a public health approach. Available at: http://www.who.int/hiv/pub/prev-care/en/ScalingUp-E.pdf. Accessed December 21, 2011.
24. Sungkanuparph S, Anekthananon T, Hiransuthikul N, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai. 2008;91:1925-1935.
25. Hess KR. Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med. 1994;13: 1045-1062. (Pubitemid 24169931)
26. National Institute of Allergy and Infectious Diseases-Division of AIDS. Table for grading the severity of adult and pediatric adverse events. Version 1.0, December 2004; Clarification August 2009. Available at: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table-for-Grading- Severity-of-Adult-Pediatric-Adverse-Events.pdf. Accessed December 21, 2011.
27. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Available at: http://www.who.int/vmnis/indicators/ haemoglobin/en/. Accessed December 21, 2011.
28. World Health Organization. Global database on body mass index-BMI classification. Available at: http://apps.who.int/bmi/index.jsp?introPage= intro-3.html. Accessed December 21, 2011.
29. Royston P. Multiple imputation of missing values: update of ice. Stata J. 2005;5:527-536. (Pubitemid 43708457)
30. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18: 681-694. (Pubitemid 29126744)
31. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 30:377-399.
32. Lawn SD, Myer L, Harling G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis. 2006;43:770-776. (Pubitemid 44330743)
33. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet. 375:123-131.
34. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007; 146:87-95. (Pubitemid 351640011)
35. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 376:449-457.
36. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach- 2010 rev. Available at: http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf. Accessed December 21, 2011.
37. WHO and UNAIDS. Guidance on provider-initiated HIV testing and counselling in health facilities. Available at: http://whqlibdoc.who.int/ publications/2007/9789241595568-eng.pdf. Accessed December 21, 2011.
38. Srasuebkul P, Lim PL, Lee MP, et al. Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin Infect Dis. 2009;48:940-950.
39. Liu E, Spiegelman D, Semu H, et al. Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania. J Infect Dis. 2011;204:282-290.
40. Palombi L, Dorrucci M, Zimba I, et al. Immunologic response to highly active antiretroviral therapy and mortality reduction in a cohort of human immunodeficiency virus-positive persons in Mozambique. Am J Trop Med Hyg. 2010;83:1128-1132.
41. Lambada M, Giganti M, Mango A, et al. Hb levels at 6 months and their Association with subsequent mortality among adults on ART in Lusaka, Zambia. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; Poster #557; 2011; Boston, M.A.
42. Volberding PA, Levine AM, Dieterich D, et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004;38:1454-1463. (Pubitemid 38668593)
43. Antiretroviral Therapy Cohort Collaboration. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007;46:607-615.
44. Maman D, Pujades-Rodriguez M, Subtil F, et al. Gender differences in long-term immune response to ART and mortality: a cohort analysis in 4 sub-Saharan HIV programs. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; Poster #557; 2011; Boston, M.A.
45. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 24:563-572.
46. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008;86:559-567. (Pubitemid 351931216)